Welcome to our dedicated page for Relmada Therapeutics SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Relmada Therapeutics, Inc. (RLMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Relmada identifies itself in these documents as a Nevada corporation with common stock listed on the Nasdaq Capital Market under the symbol RLMD and principal offices in Coral Gables, Florida.
Through forms such as Form 8‑K, Relmada reports material events related to its business. Recent 8‑K filings describe topics including: written FDA feedback on planned Phase 3 registrational trials for NDV-01 in non-muscle invasive bladder cancer; preliminary nine‑month safety and efficacy data from the NDV-01 Phase 2 study; quarterly financial updates; an underwritten offering of common stock and pre-funded warrants; Nasdaq minimum bid price compliance matters; and amendments to executive employment agreements. These filings often incorporate press releases as exhibits and summarize key financial or clinical information referenced in company news.
Investors interested in capital structure and financing can review 8‑K disclosures regarding the terms of underwritten offerings, pre-funded warrants, and related legal opinions. Those focused on governance and compensation can examine filings detailing amended and restated employment agreements for executive officers, including changes to salary and severance provisions.
While this page emphasizes current and historical 8‑K reports, Relmada also files other periodic and registration statements, such as Forms 10‑Q, 10‑K, and S‑3, that contain more extensive financial statements, risk factor discussions, and descriptions of its NDV-01 and sepranolone development programs. Stock Titan enhances access to these documents by pairing them with AI-powered tools that help explain filing contents, highlight key sections, and make it easier to locate information on topics such as clinical trial plans, cash resources, listing status, and executive arrangements.
Relmada Therapeutics (RLMD) is asking shareholders to elect two directors and approve routine housekeeping proposals while describing a strategic turnaround completed in 2025. Management reports two clinical-stage acquisitions (NDV-01 and sepranolone), a successful $100 million financing in November, and a recovery in market value from a low of $0.24 to a post-financing high of $4.83.
The company reports cash increasing to approximately $100 million after the financing, retention and strengthening of its core team, planned Phase 2 and Phase 3 milestones for NDV-01 and sepranolone in mid-2026, and seeks shareholder approval to increase equity plan reserves by 3.0 million shares and authorized common shares from 150,000,000 to 200,000,000.
Relmada Therapeutics, Inc. filed a preliminary prospectus on a registration statement to register the resale of 33,685,096 shares of common stock, consisting of 29,474,569 issued shares and 4,210,527 shares underlying pre-funded warrants issued in a private placement. The shares are being registered for resale by the selling stockholders and the company will not receive proceeds from those resales. The private placement closed March 11, 2026 for aggregate gross proceeds of approximately $160.0 million (shares at $4.75 and pre-funded warrants at $4.749). Shares outstanding were 104,888,233 as of March 20, 2026; the last reported sale price was $6.99 per share on April 2, 2026.
Relmada Therapeutics reported audited 2025 results and a major strategic shift toward oncology, led by NDV-01 for non-muscle invasive bladder cancer. For 2025, the company recorded a net loss of $57.4 million, an improvement from $80.0 million in 2024, as total operating expenses fell to $59.1 million from $83.9 million. Research and development spending declined to $26.9 million and general and administrative costs to $32.2 million.
Total assets rose to $94.0 million as of December 31, 2025, driven by cash and short-term investments of about $94.0 million and common shares outstanding increasing to 73.3 million. A separate $160 million PIPE financing and the year-end balance sheet underpin management’s view that cash resources should fund operations through 2029.
Clinically, 12‑month Phase 2a data for NDV‑01 showed high complete response rates in high‑risk NMIBC, including a 3‑month complete response in 95% of evaluable patients and 76% at 12 months, with no Grade 3 or higher treatment‑related adverse events and no treatment‑related discontinuations. The FDA has agreed to two registrational pathways for NDV‑01, and Relmada plans to start the Phase 3 RESCUE program and a Phase 2b trial of sepranolone in Prader‑Willi syndrome in mid‑2026.
Relmada Therapeutics, Inc. filed its annual report detailing a major strategic pivot away from esmethadone and psilocybin programs toward two new lead assets, NDV-01 for non–muscle-invasive bladder cancer and sepranolone for Prader–Willi syndrome and related disorders.
The company in-licensed NDV-01 and acquired sepranolone in early 2025, and reported encouraging Phase 2 NDV-01 data with high complete response rates in high‑grade and BCG‑unresponsive NMIBC. Relmada remains a clinical‑stage company with no approved products, recording a $57.4 million net loss in 2025 versus $80.0 million in 2024, and an accumulated deficit of about $698.3 million.
As of December 31, 2025, cash, cash equivalents and short‑term investments were approximately $93.0 million, and as of March 16, 2026 there were 104,890,223 common shares outstanding. The filing emphasizes significant clinical, regulatory, funding and execution risks around the new pipeline‑focused strategy.
Relmada Therapeutics entered into a private placement securities purchase agreement with institutional and accredited investors for approximately $160.0 million, selling 29,474,569 common shares at $4.75 and pre-funded warrants for 4,210,527 shares at $4.749 with a $0.001 exercise price. Closing is expected on March 11, 2026, and proceeds are earmarked for working capital and to advance research and development of its product candidates. Investors receive registration rights for resale and liquidated damages if registration timelines are missed.
The company also reported 12‑month interim Phase 2 NDV‑01 data in high‑risk non‑muscle invasive bladder cancer, showing a 12‑month complete response rate of 76% overall and 80% in the BCG‑unresponsive subgroup, with no progression to muscle‑invasive disease or radical cystectomies. These results support moving NDV‑01 into the Phase 3 RESCUE registrational program across both adjuvant intermediate‑risk and second‑line BCG‑unresponsive settings.
Relmada Therapeutics, Inc. received an updated ownership report showing a near-10% stake held by Squadron-affiliated funds and principals. Squadron Master Fund LP, together with Squadron Capital Management, LLC, William Blank, and Matthew Sesterhenn, report beneficial ownership of 7,395,510 shares of Common Stock.
This position consists of 6,700,000 common shares plus 695,510 shares issuable upon exercise of warrants held by Squadron Capital Management, LLC. Based on 73,333,622 shares outstanding as of November 10, 2025, plus these warrant shares, the group’s holdings represent approximately 9.99% of Relmada’s common stock.
The Squadron entities and individuals report shared voting and dispositive power over all 7,395,510 shares and no sole power. The investment adviser and its partners expressly disclaim beneficial ownership and state that the securities are held in the ordinary course of business, not for the purpose of changing or influencing control of Relmada.
Relmada Therapeutics, Inc. disclosed that investment manager Spruce Street Capital LP, together with Alex R. Rosen and Simon Basseyn, reported beneficial ownership of 4,086,181 shares of common stock, representing 5.57% of the company. This percentage is based on 73,333,622 shares outstanding as of November 10, 2025. The investors certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Relmada.
Relmada Therapeutics, Inc. is the subject of a Schedule 13G showing that Adage Capital Management, L.P. and related individuals beneficially own 4,270,000 shares of its common stock, representing 5.82% of the class. This percentage is based on 73,333,622 shares outstanding as of November 10, 2025.
The reporting persons have shared voting and dispositive power over all reported shares and no sole power. They state the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Relmada Therapeutics.
Janus Henderson Group plc filed a Schedule 13G reporting beneficial ownership of 7,439,415 shares of Relmada Therapeutics, Inc. common stock, representing 10.1% of the class. The shares are held across various managed portfolios of Janus Henderson’s asset management subsidiaries, which exercise investment and voting discretion.
Janus Henderson reports shared voting and shared dispositive power over all reported shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Relmada Therapeutics.
Relmada Therapeutics, Inc. has updated its at-the-market stock sales program to offer up to $100,000,000 of common stock through Jefferies LLC as sales agent under an existing Open Market Sale Agreement.
The company states it has not previously sold any shares under this program and is amending the prior prospectus materials to reflect the higher aggregate amount. Relmada’s common stock trades on the Nasdaq Global Select Market under the symbol RLMD, and the last reported sale price was $3.91 per share on January 29, 2026. The company also notes it is no longer subject to the Form S-3 General Instruction I.B.6 limitations because the aggregate market value of its non-affiliate holdings was at least $75.0 million as of January 28, 2026.